Q1: 2026-05-05 Earnings Summary
EPS of -$1.37 beats by $0.59
| Revenue of $40.79M (28.11% Y/Y) beats by $1.63M
GRAIL, Inc. (GRAL) Bank of America Global Healthcare Conference 2026 May 12, 2026 11:40 AM EDT
Company Participants
Aaron Freidin – Chief Financial Officer
Conference Call Participants
Michael Ryskin – BofA Securities, Research Division
Conversation
Aaron Freidin
Chief Financial Officer
[Audio Gap] Our digital health channels. It’s been great to see there despite some of the NHS headlines, the growth persisted and so on. So really excited to be there. For the rest of the year, we’ve got — we’ve announced we’re going to implement Epic by the end of the year. We continue to see momentum from some of our other integrations, whether it’s Quest or Athenahealth and the pull-through is there. So it’s great to see…
Michael Ryskin
BofA Securities, Research Division
Maybe let’s — you mentioned NHS. — let’s just dive right into that. That was sort of the big update that happened during the quarter. A lot to parse apart there. Has that impacted any of your customers or in your conversations around demand? So has that had any impact on the business as you see it in terms of like volume?
Aaron Freidin
Chief Financial Officer
Yes. So I’d say that the headline came out and physicians who are orderers, physicians who are prospective orderers ask more questions. It was pretty clear though that those who saw beyond the headline and saw some of the clinical utility measures such as Stage IV reduction, increase in Stage I and II, decreased emergency room presentations, 4x more cancers found than the standard of care, like they got it. That all being said, everyone wants to see the data at ASCO. It’s one of those SEC disclosure type things where you’ve got data in-house, you’ve got to say something vague, to not protect your — I mean, to not ruin your ASCO presentation. So everybody wants to see the ASCO data, and that will
